Indication

Hormone-Sensitive Prostate Cancer

1 clinical trial

1 product

1 drug

Clinical trial

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.

Status: Active (not recruiting), Estimated PCD: 2024-10-04

Product

Drug

Abiraterone Acetate